Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

1644 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
GL
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
AQ
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
AQ
Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K
PU
Oxford Biomedica : 2024 Notice of Annual General Meeting
PU
Oxford Biomedica : 2024 Notice of Annual General Meeting 15 May 2024
PU
Curis Announces Additional Data from TakeAim Leukemia Study
PR
Transcript : Information Services Corporation - Shareholder/Analyst Call
Transcript : Equites Property Fund Limited, 2024 Earnings Call, May 14, 2024
Transcript : Thinkific Labs Inc., Q1 2024 Earnings Call, May 07, 2024
Fidelity Investment Trust Fidelity Special Values : Special Values PLC Half-Yearly Report for the six months ended 29 February 2024
PU
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Fidelity Special Values Plc - Half-year Report
PR
Ballard Power : Management Proxy Circular - Form 6-K
PU
Transcript : L'Oréal S.A., Q1 2024 Sales/ Trading Statement Call, Apr 18, 2024
Moderna : 2024 Proxy Statement
PU
Moderna : AACR INT Head & Neck Poster
PU
Ballard Announces Appointment of Jacqui Dedo to Board of Directors
PR
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.
AQ
Transcript : IP Group Plc, Q4 2023 Earnings Call, Mar 13, 2024
Societe Generale : Note ANC 2016.09_EN
PU
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47
AQ
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
BU
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
GL
Roche's Xolair reduces reactions to severe food allergies in study
RE
Transcript : L'Oréal S.A. Presents at 2024 Consumer Analyst Group of New York Conference, Feb-23-2024 09:00 AM
Transcript : Ionis Pharmaceuticals, Inc., 2023 Earnings Call, Feb 21, 2024
Transcript : Graphic Packaging Holding Company - Analyst/Investor Day
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GL
StepStone Group LP Announces Executive Promotions
CI
Icon Singapore holds inaugural Regional Oncology Conference
AQ
Icon Singapore holds inaugural Radiation Oncology Conference
AQ
Immunome Appoints Phil Roberts as Chief Technical Officer
CI
Immunome Appoints Phil Roberts as Chief Technical Officer
BU
IAMGOLD : TECHNICAL REPORT ON THE ESSAKANE GOLD MINE, SAHEL REGION, BURKINA FASO - Form 6-K
PU
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
AQ
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
AQ
Transcript : Ramsay Health Care Limited - Shareholder/Analyst Call
Ramsay Health Care : 2023 Impact Report
PU
Transcript : Lineage Cell Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Transcript : Ionis Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Regeneron Reports Third Quarter 2023 Financial and Operating Results
GL
GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
PU
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
BU
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
GL
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
BU
HARPOON THERAPEUTICS ANNOUNCES FIRST PATIENTS WITH SMALL CELL LUNG CANCER DOSED IN HPN328 COMBINATION COHORT
AQ
Pacific Edge : Lotan et al Commentary on Novitas LCD DL39365
PU
Transcript : Cloud DX Inc., Q2 2023 Earnings Call, Aug 29, 2023
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
BU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Robert Roche
  4. News